Danger Dust
Bampot
•
1w ago
•
100%
Dual immunotherapy plus chemotherapy found to benefit specific subset of patients with lung cancer
medicalxpress.comResearchers from The University of Texas MD Anderson Cancer Center have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor genes were more likely to benefit from adding the immunotherapy tremelimumab to a combination of durvalumab plus chemotherapy to overcome treatment resistance typically seen in this patient population.
Comments 0